The clinical efficacy of apatinib mesylate in the treatment of recurrent metastatic breast cancer

ObjectiveTo investigate the efficacy and safety of apatinib mesylate in the treatment of advanced recurrent metastatic breast cancer.

MethodsThe clinical data of 25 advanced recurrent metastatic breast cancer patients with more than 3-line treatment failure were retrospectively analyzed.The objective response rate, disease control rate, progress free survival, overall survival and safety in patients treated with oral apatinib mesylate were evaluated.

ResultsAmong 25 patients, the disease stabliation in 11 cases, partial remission in 4 cases and disease progression in 10 cases were identified.The objective response rate, disease control rate, median progress free survival and overall survival were 16.0%, 60.0%, 3.68 months and 16.06 months, respectively.The results of multi-factor analysis showed that the number of chemotherapy and ER status were the influencing factors of progress free survival(P < 0.05).The hypertension, fatigue, hand-foot syndrome and diarrhea were the main adverse reactions of apatinib, and no serious adverse reactions in 25 patients were found.

ConclusionThe apatinib mesylate in the treatment of advanced recurrent metastatic breast cancer has high efficacy, the adverse reactions is controllable, and the quality of life of patients can be improved, which is worthy of further study.